InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,762.48
(
0.42%
)
US TECH 100
19,481.60
(
0.06%
)
Dow Jones
42,330.15
(
0.04%
)
Brent Oil
71.84
(
-0.21%
)
Bitcoin
63,308.50
(
-0.03%
)
Post# of 253260
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2624
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: DewDiligence post# 143882

Thursday, 06/14/2012 2:17:57 PM

Thursday, June 14, 2012 2:17:57 PM

Post# of 253260

IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.



I think the neuro's will tell their patients unless they think compliance would suffer - which I think it would. It is easier to get in the habit of doing something every day.

IF there is no change in the NCE, why couldn't the generic provider get approval for the new thrice weekly dose?

ij

It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up